Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.
Identifieur interne : 002504 ( Main/Exploration ); précédent : 002503; suivant : 002505Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.
Auteurs : Steve Rockman [Australie] ; Sarina Camuglia ; Kirsten Vandenberg ; Chi Ong ; Mark A. Baker ; Roger L. Nation ; Jian Li ; Tony VelkovSource :
- Molecular immunology [ 1872-9142 ] ; 2013.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Anticorps antiviraux (composition chimique), Anticorps antiviraux (immunologie), Anticorps monoclonaux (composition chimique), Anticorps monoclonaux (immunologie), Anticorps neutralisants (composition chimique), Anticorps neutralisants (immunologie), Antigènes viraux (génétique), Antigènes viraux (immunologie), Cartographie épitopique (MeSH), Données de séquences moléculaires (MeSH), Glycoprotéine hémagglutinine du virus influenza (composition chimique), Glycoprotéine hémagglutinine du virus influenza (génétique), Glycoprotéine hémagglutinine du virus influenza (immunologie), Génie génétique (MeSH), Génétique inverse (MeSH), Humains (MeSH), Modèles moléculaires (MeSH), Mutation (MeSH), Oiseaux (immunologie), Oiseaux (virologie), Réactions croisées (MeSH), Sialidase (composition chimique), Sialidase (génétique), Sialidase (immunologie), Sous-type H5N1 du virus de la grippe A (génétique), Sous-type H5N1 du virus de la grippe A (immunologie), Séquence d'acides aminés (MeSH), Tests de neutralisation (MeSH), Épitopes (composition chimique), Épitopes (génétique), Épitopes (immunologie).
- MESH :
- composition chimique : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Glycoprotéine hémagglutinine du virus influenza, Sialidase, Épitopes.
- génétique : Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza, Sialidase, Sous-type H5N1 du virus de la grippe A, Épitopes.
- immunologie : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants, Antigènes viraux, Glycoprotéine hémagglutinine du virus influenza, Oiseaux, Sialidase, Sous-type H5N1 du virus de la grippe A, Épitopes.
- virologie : Oiseaux.
- Animaux, Cartographie épitopique, Données de séquences moléculaires, Génie génétique, Génétique inverse, Humains, Modèles moléculaires, Mutation, Réactions croisées, Séquence d'acides aminés, Tests de neutralisation.
English descriptors
- KwdEn :
- Amino Acid Sequence (MeSH), Animals (MeSH), Antibodies, Monoclonal (chemistry), Antibodies, Monoclonal (immunology), Antibodies, Neutralizing (chemistry), Antibodies, Neutralizing (immunology), Antibodies, Viral (chemistry), Antibodies, Viral (immunology), Antigens, Viral (genetics), Antigens, Viral (immunology), Birds (immunology), Birds (virology), Cross Reactions (MeSH), Epitope Mapping (MeSH), Epitopes (chemistry), Epitopes (genetics), Epitopes (immunology), Genetic Engineering (MeSH), Hemagglutinin Glycoproteins, Influenza Virus (chemistry), Hemagglutinin Glycoproteins, Influenza Virus (genetics), Hemagglutinin Glycoproteins, Influenza Virus (immunology), Humans (MeSH), Influenza A Virus, H5N1 Subtype (genetics), Influenza A Virus, H5N1 Subtype (immunology), Models, Molecular (MeSH), Molecular Sequence Data (MeSH), Mutation (MeSH), Neuraminidase (chemistry), Neuraminidase (genetics), Neuraminidase (immunology), Neutralization Tests (MeSH), Reverse Genetics (MeSH).
- MESH :
- chemical , chemistry : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Neuraminidase.
- chemical , genetics : Antigens, Viral, Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Neuraminidase.
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral, Antigens, Viral, Epitopes, Hemagglutinin Glycoproteins, Influenza Virus, Neuraminidase.
- genetics : Influenza A Virus, H5N1 Subtype.
- immunology : Birds, Influenza A Virus, H5N1 Subtype.
- virology : Birds.
- Amino Acid Sequence, Animals, Cross Reactions, Epitope Mapping, Genetic Engineering, Humans, Models, Molecular, Molecular Sequence Data, Mutation, Neutralization Tests, Reverse Genetics.
Abstract
The induction of neutralising antibodies to the viral surface glycoprotein, haemagglutinin (HA) is considered the cornerstone of current seasonal and pandemic influenza vaccines. Mapping of neutralising epitopes using monoclonal antibodies (mAbs) helps define mechanisms of antigenic drift, neutralising escape and facilitates pre-pandemic vaccine design. In the present study we reverse engineered the antigenic structure of the HAs of two highly pathogenic H5N1 vaccine strains representative of currently circulating clade 1 and 2.2 H5N1 viruses. The HA sequence of the A/Vietnam/1194/04 clade 1 virus was progressively mutated into the HA sequence of the clade 2.2 virus, A/Bar-headed Goose/Qinghai/1A/05. Fine mapping of clade-specific neutralising epitopes was performed by examining the cross-reactivity of mAbs raised against the native HA of each parent virus. The reactivity across all clade specific mAbs centred around a constellation of mutations at positions 140, 145, 171 and 172, all of which are proximal to the receptor binding site on the membrane distal globular head of the HA. Overlapping cross-reactivity of these antigenic sites suggests that these amino acid positions relate to the antigenic evolution of the H5 clade 1 and 2.2 viruses. This finding may prove useful for the design of vaccines with broader neutralising cross-reactivity against the different H5 HA sublineages currently in circulation. These findings provide important information about the amino acid changes involved in the cross-clade evolution of H5N1 viruses and their potential for human to human transmission; and facilitates a greater understanding of the pandemic potential of H5N1 isolates.
DOI: 10.1016/j.molimm.2012.10.001
PubMed: 23127859
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.</title>
<author><name sortKey="Rockman, Steve" sort="Rockman, Steve" uniqKey="Rockman S" first="Steve" last="Rockman">Steve Rockman</name>
<affiliation wicri:level="1"><nlm:affiliation>CSL Limited Poplar Road, Parkville, 3052 Victoria, Australia. Steve.Rockman@csl.com.au</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSL Limited Poplar Road, Parkville, 3052 Victoria</wicri:regionArea>
<wicri:noRegion>3052 Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Camuglia, Sarina" sort="Camuglia, Sarina" uniqKey="Camuglia S" first="Sarina" last="Camuglia">Sarina Camuglia</name>
</author>
<author><name sortKey="Vandenberg, Kirsten" sort="Vandenberg, Kirsten" uniqKey="Vandenberg K" first="Kirsten" last="Vandenberg">Kirsten Vandenberg</name>
</author>
<author><name sortKey="Ong, Chi" sort="Ong, Chi" uniqKey="Ong C" first="Chi" last="Ong">Chi Ong</name>
</author>
<author><name sortKey="Baker, Mark A" sort="Baker, Mark A" uniqKey="Baker M" first="Mark A" last="Baker">Mark A. Baker</name>
</author>
<author><name sortKey="Nation, Roger L" sort="Nation, Roger L" uniqKey="Nation R" first="Roger L" last="Nation">Roger L. Nation</name>
</author>
<author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
</author>
<author><name sortKey="Velkov, Tony" sort="Velkov, Tony" uniqKey="Velkov T" first="Tony" last="Velkov">Tony Velkov</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23127859</idno>
<idno type="pmid">23127859</idno>
<idno type="doi">10.1016/j.molimm.2012.10.001</idno>
<idno type="wicri:Area/Main/Corpus">002819</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">002819</idno>
<idno type="wicri:Area/Main/Curation">002819</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">002819</idno>
<idno type="wicri:Area/Main/Exploration">002819</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.</title>
<author><name sortKey="Rockman, Steve" sort="Rockman, Steve" uniqKey="Rockman S" first="Steve" last="Rockman">Steve Rockman</name>
<affiliation wicri:level="1"><nlm:affiliation>CSL Limited Poplar Road, Parkville, 3052 Victoria, Australia. Steve.Rockman@csl.com.au</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSL Limited Poplar Road, Parkville, 3052 Victoria</wicri:regionArea>
<wicri:noRegion>3052 Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Camuglia, Sarina" sort="Camuglia, Sarina" uniqKey="Camuglia S" first="Sarina" last="Camuglia">Sarina Camuglia</name>
</author>
<author><name sortKey="Vandenberg, Kirsten" sort="Vandenberg, Kirsten" uniqKey="Vandenberg K" first="Kirsten" last="Vandenberg">Kirsten Vandenberg</name>
</author>
<author><name sortKey="Ong, Chi" sort="Ong, Chi" uniqKey="Ong C" first="Chi" last="Ong">Chi Ong</name>
</author>
<author><name sortKey="Baker, Mark A" sort="Baker, Mark A" uniqKey="Baker M" first="Mark A" last="Baker">Mark A. Baker</name>
</author>
<author><name sortKey="Nation, Roger L" sort="Nation, Roger L" uniqKey="Nation R" first="Roger L" last="Nation">Roger L. Nation</name>
</author>
<author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
</author>
<author><name sortKey="Velkov, Tony" sort="Velkov, Tony" uniqKey="Velkov T" first="Tony" last="Velkov">Tony Velkov</name>
</author>
</analytic>
<series><title level="j">Molecular immunology</title>
<idno type="eISSN">1872-9142</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence (MeSH)</term>
<term>Animals (MeSH)</term>
<term>Antibodies, Monoclonal (chemistry)</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Neutralizing (chemistry)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (chemistry)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antigens, Viral (genetics)</term>
<term>Antigens, Viral (immunology)</term>
<term>Birds (immunology)</term>
<term>Birds (virology)</term>
<term>Cross Reactions (MeSH)</term>
<term>Epitope Mapping (MeSH)</term>
<term>Epitopes (chemistry)</term>
<term>Epitopes (genetics)</term>
<term>Epitopes (immunology)</term>
<term>Genetic Engineering (MeSH)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (chemistry)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus (immunology)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H5N1 Subtype (genetics)</term>
<term>Influenza A Virus, H5N1 Subtype (immunology)</term>
<term>Models, Molecular (MeSH)</term>
<term>Molecular Sequence Data (MeSH)</term>
<term>Mutation (MeSH)</term>
<term>Neuraminidase (chemistry)</term>
<term>Neuraminidase (genetics)</term>
<term>Neuraminidase (immunology)</term>
<term>Neutralization Tests (MeSH)</term>
<term>Reverse Genetics (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term>
<term>Anticorps antiviraux (composition chimique)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps monoclonaux (composition chimique)</term>
<term>Anticorps monoclonaux (immunologie)</term>
<term>Anticorps neutralisants (composition chimique)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Antigènes viraux (génétique)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Cartographie épitopique (MeSH)</term>
<term>Données de séquences moléculaires (MeSH)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (composition chimique)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term>
<term>Glycoprotéine hémagglutinine du virus influenza (immunologie)</term>
<term>Génie génétique (MeSH)</term>
<term>Génétique inverse (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Modèles moléculaires (MeSH)</term>
<term>Mutation (MeSH)</term>
<term>Oiseaux (immunologie)</term>
<term>Oiseaux (virologie)</term>
<term>Réactions croisées (MeSH)</term>
<term>Sialidase (composition chimique)</term>
<term>Sialidase (génétique)</term>
<term>Sialidase (immunologie)</term>
<term>Sous-type H5N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H5N1 du virus de la grippe A (immunologie)</term>
<term>Séquence d'acides aminés (MeSH)</term>
<term>Tests de neutralisation (MeSH)</term>
<term>Épitopes (composition chimique)</term>
<term>Épitopes (génétique)</term>
<term>Épitopes (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Epitopes</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term>
<term>Epitopes</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
<term>Epitopes</term>
<term>Hemagglutinin Glycoproteins, Influenza Virus</term>
<term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Sialidase</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Sialidase</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps monoclonaux</term>
<term>Anticorps neutralisants</term>
<term>Antigènes viraux</term>
<term>Glycoprotéine hémagglutinine du virus influenza</term>
<term>Oiseaux</term>
<term>Sialidase</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Birds</term>
<term>Influenza A Virus, H5N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Oiseaux</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Birds</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Cross Reactions</term>
<term>Epitope Mapping</term>
<term>Genetic Engineering</term>
<term>Humans</term>
<term>Models, Molecular</term>
<term>Molecular Sequence Data</term>
<term>Mutation</term>
<term>Neutralization Tests</term>
<term>Reverse Genetics</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cartographie épitopique</term>
<term>Données de séquences moléculaires</term>
<term>Génie génétique</term>
<term>Génétique inverse</term>
<term>Humains</term>
<term>Modèles moléculaires</term>
<term>Mutation</term>
<term>Réactions croisées</term>
<term>Séquence d'acides aminés</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The induction of neutralising antibodies to the viral surface glycoprotein, haemagglutinin (HA) is considered the cornerstone of current seasonal and pandemic influenza vaccines. Mapping of neutralising epitopes using monoclonal antibodies (mAbs) helps define mechanisms of antigenic drift, neutralising escape and facilitates pre-pandemic vaccine design. In the present study we reverse engineered the antigenic structure of the HAs of two highly pathogenic H5N1 vaccine strains representative of currently circulating clade 1 and 2.2 H5N1 viruses. The HA sequence of the A/Vietnam/1194/04 clade 1 virus was progressively mutated into the HA sequence of the clade 2.2 virus, A/Bar-headed Goose/Qinghai/1A/05. Fine mapping of clade-specific neutralising epitopes was performed by examining the cross-reactivity of mAbs raised against the native HA of each parent virus. The reactivity across all clade specific mAbs centred around a constellation of mutations at positions 140, 145, 171 and 172, all of which are proximal to the receptor binding site on the membrane distal globular head of the HA. Overlapping cross-reactivity of these antigenic sites suggests that these amino acid positions relate to the antigenic evolution of the H5 clade 1 and 2.2 viruses. This finding may prove useful for the design of vaccines with broader neutralising cross-reactivity against the different H5 HA sublineages currently in circulation. These findings provide important information about the amino acid changes involved in the cross-clade evolution of H5N1 viruses and their potential for human to human transmission; and facilitates a greater understanding of the pandemic potential of H5N1 isolates.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23127859</PMID>
<DateCompleted><Year>2013</Year>
<Month>03</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>01</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9142</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>53</Volume>
<Issue>4</Issue>
<PubDate><Year>2013</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>Molecular immunology</Title>
<ISOAbbreviation>Mol Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies.</ArticleTitle>
<Pagination><MedlinePgn>435-42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molimm.2012.10.001</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0161-5890(12)00415-4</ELocationID>
<Abstract><AbstractText>The induction of neutralising antibodies to the viral surface glycoprotein, haemagglutinin (HA) is considered the cornerstone of current seasonal and pandemic influenza vaccines. Mapping of neutralising epitopes using monoclonal antibodies (mAbs) helps define mechanisms of antigenic drift, neutralising escape and facilitates pre-pandemic vaccine design. In the present study we reverse engineered the antigenic structure of the HAs of two highly pathogenic H5N1 vaccine strains representative of currently circulating clade 1 and 2.2 H5N1 viruses. The HA sequence of the A/Vietnam/1194/04 clade 1 virus was progressively mutated into the HA sequence of the clade 2.2 virus, A/Bar-headed Goose/Qinghai/1A/05. Fine mapping of clade-specific neutralising epitopes was performed by examining the cross-reactivity of mAbs raised against the native HA of each parent virus. The reactivity across all clade specific mAbs centred around a constellation of mutations at positions 140, 145, 171 and 172, all of which are proximal to the receptor binding site on the membrane distal globular head of the HA. Overlapping cross-reactivity of these antigenic sites suggests that these amino acid positions relate to the antigenic evolution of the H5 clade 1 and 2.2 viruses. This finding may prove useful for the design of vaccines with broader neutralising cross-reactivity against the different H5 HA sublineages currently in circulation. These findings provide important information about the amino acid changes involved in the cross-clade evolution of H5N1 viruses and their potential for human to human transmission; and facilitates a greater understanding of the pandemic potential of H5N1 isolates.</AbstractText>
<CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rockman</LastName>
<ForeName>Steve</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>CSL Limited Poplar Road, Parkville, 3052 Victoria, Australia. Steve.Rockman@csl.com.au</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Camuglia</LastName>
<ForeName>Sarina</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vandenberg</LastName>
<ForeName>Kirsten</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ong</LastName>
<ForeName>Chi</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Baker</LastName>
<ForeName>Mark A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nation</LastName>
<ForeName>Roger L</ForeName>
<Initials>RL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Jian</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Velkov</LastName>
<ForeName>Tony</ForeName>
<Initials>T</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>11</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Mol Immunol</MedlineTA>
<NlmUniqueID>7905289</NlmUniqueID>
<ISSNLinking>0161-5890</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C109963">hemagglutinin, avian influenza A virus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001717" MajorTopicYN="N">Birds</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D059386" MajorTopicYN="Y">Reverse Genetics</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>09</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2012</Year>
<Month>10</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2012</Year>
<Month>10</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>11</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>11</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2013</Year>
<Month>3</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23127859</ArticleId>
<ArticleId IdType="pii">S0161-5890(12)00415-4</ArticleId>
<ArticleId IdType="doi">10.1016/j.molimm.2012.10.001</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><noCountry><name sortKey="Baker, Mark A" sort="Baker, Mark A" uniqKey="Baker M" first="Mark A" last="Baker">Mark A. Baker</name>
<name sortKey="Camuglia, Sarina" sort="Camuglia, Sarina" uniqKey="Camuglia S" first="Sarina" last="Camuglia">Sarina Camuglia</name>
<name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
<name sortKey="Nation, Roger L" sort="Nation, Roger L" uniqKey="Nation R" first="Roger L" last="Nation">Roger L. Nation</name>
<name sortKey="Ong, Chi" sort="Ong, Chi" uniqKey="Ong C" first="Chi" last="Ong">Chi Ong</name>
<name sortKey="Vandenberg, Kirsten" sort="Vandenberg, Kirsten" uniqKey="Vandenberg K" first="Kirsten" last="Vandenberg">Kirsten Vandenberg</name>
<name sortKey="Velkov, Tony" sort="Velkov, Tony" uniqKey="Velkov T" first="Tony" last="Velkov">Tony Velkov</name>
</noCountry>
<country name="Australie"><noRegion><name sortKey="Rockman, Steve" sort="Rockman, Steve" uniqKey="Rockman S" first="Steve" last="Rockman">Steve Rockman</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002504 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002504 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= PoplarV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:23127859 |texte= Reverse engineering the antigenic architecture of the haemagglutinin from influenza H5N1 clade 1 and 2.2 viruses with fine epitope mapping using monoclonal antibodies. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23127859" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a PoplarV1
This area was generated with Dilib version V0.6.37. |